PURPOSE: The aim of this study was to elicit utilities for radioactive @entity1496 -refractory differentiated @entity259 (RR-DTC) and evaluate the impact of treatment response and @entity137 on quality of life. @entity1 AND METHODS: RR-DTC health states were developed based on data from a previous qualitative study and iterative review by clinical experts. Following piloting, health states underwent valuation by 100 members of the UK public during time trade-off interviews. Mean utilities and descriptive distribution statistics were calculated, and a logistic regression analysis was conducted. RESULTS: The demographic characteristics of the study sample were generally reflective of the UK population. Clear differentiation in valuation between health states was observed. No response/stable disease had an adjusted utility value of 0.87, with a corresponding gain of +0.04 following a treatment response and a decline of -0.35 for disease progression. Adverse events were associated with utility decrements between -0.47 (grade III @entity294 ) and -0.05 (grade I/II alopecia). CONCLUSION: The trade-off interviews derived utility weights show clear differentiation between RR-DTC health states in response to treatment. The values reported in this study are suitable for cost-effectiveness evaluations for new treatments in RR-DTC.

Health state utility valuation in radioactive @entity1496 -refractory differentiated XXXX .

@entity1 :: ('9606', 'Species') :: ['PATIENTS'] @entity1496 :: ('MESH:D007455', 'Chemical') :: ['iodine'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity259 :: ('MESH:D013964', 'Disease') :: ['thyroid cancer']
@entity259 :: (MESH:D013964,Disease) :: ['thyroid cancer']
